Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Описание: Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury’s analysts discuss the rise in large M&A deals (https://www.biocentury.com/article/65...) and what the trends (https://www.biocentury.com/article/65...) among the 37 acquisitions say about biopharma dealmaking.
The analysts assess first-in-human in vivo CAR T data at the American Society of Hematology meeting from Kelonia Therapeutics, which showcase the promise of the modality and justify the growing pipeline. They also break down readouts from Praxis in developmental and epileptic encephalopathy (https://www.biocentury.com/article/65...) from the American Epilepsy Society Annual Meeting and from Novo Nordisk, which presented (https://www.biocentury.com/article/65...) full data at the Clinical Trials on Alzheimer’s Disease meeting on semaglutide’s failure to treat Alzheimer’s disease.
Washington Editor Steve Usdin analyzes a roller-coaster week at FDA in which Richard Pazdur resigned (https://www.biocentury.com/article/65...) as director of FDA’s Center for Drug Evaluation and Research and Tracy Beth Høeg became acting CDER director, a move that Usdin says (https://www.biocentury.com/article/65...) will prompt staff departures, ease restraints on FDA leaders

View full story: https://www.biocentury.com/article/65...

#BiotechMA #CARTTherapy #EpilepsyResearch #AlzheimersDisease #FDA

02:37 - Biotech M&A
06:39 - In vivo CAR T
10:08 - Semaglutide for Alzheimer's
16:17 - Praxis
22:11 - FDA

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].


Reach us by sending a text (https://www.buzzsprout.com/twilio/tex...)